- Home
- / Aminex Therapeutics
Aminex Therapeutics
Total Funding
$16 M
Aminex Therapeutics Summary
Company Summary
- Overview
- Aminex Therapeutics is a company intended to develop small molecule immunotherapeutic products for cancer treatment. Its immunotherapy approach combines polyamine uptake inhibitor, AMXT 1501, and polyamine synthesis inhibitor DFMO.
- Type
- Private
- Status
- Active
- Founded
- 2009
- Website
- https://aminextx.com/
- Cybersecurity rating
Table of Contents
Key People
Mark Burns, President & Chief Scientific Officer, Director
Stacy Hock, Director
Nicole Gallegos, Consultant, Director of Clinical Operations
